CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD
Private Wellness Club Continuum Unlocks Final Membership Tier at West Village Flagship
Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach
KLAS Report Shows Strong Early Results for TrustCommerce Cloud Payments
BioFlorida Announces Appointment of Dr. Anthony Japour, CEO of iTolerance, Inc., as Chair of the Southeast Chapter
LOS ANGELES, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the acquisition of Dynalab Corp. (the “Company”), a...
Topline safety, antiviral effectiveness and pharmacokinetic (PK) data from a Phase 1b Study in China are released from the single...
Fourth Quarter revenue of $31.7 - $31.9 million representing growth of approximately 26%Fiscal Year 2022 revenue of $106.1 - $106.3...
NGM Bio’s three-pronged corporate strategy includes the following components:Focus internal clinical development efforts on solid tumor oncology portfolioGenerate next-generation biologics...
Company is on track to move into the clinic with its lead targeted therapeutics programSAN DIEGO, Jan. 09, 2023 (GLOBE...
-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M,...
Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with...
- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with...
- Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mg/kg, generally consistent...
ROCKVILLE, Md., Jan. 06, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company...
EMERYVILLE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”), the Biotech Royalty Aggregator,...
BEDFORD, Mass., and SHANGHAI, China, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Frontera Therapeutics, a global clinical-stage biotechnology company that seeks...
BOSTON, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”; Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary...
DENVER, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative...
– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 –...
Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit in three early studies Data...
NXC-201 treatment continues to demonstrate 100% complete response rate in 6 relapsed/refractory AL amyloidosis patients to-dateClinical data published December 2022...
WARSAW, Ind., Jan. 06, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively...
NXC-201 treatment continues to demonstrate 100% complete response rate in 6 relapsed/refractory AL amyloidosis patients to-dateClinical data published December 2022...
As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH...
